Poster-Disease-modifying Therapy
October 25, 2021
Is There Wearing Off with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).
Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....
Poster-Disease-modifying Therapy
October 25, 2021
Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study
Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...
Poster-Disease-modifying Therapy
October 25, 2021
Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models
Background: Disease modifying therapies (DMTs) for relapsing MS are most effective when patients adhere to them as prescribed. Published...
Poster-Disease-modifying Therapy
October 25, 2021
Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data
Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem
Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefitrisk profile in patients with relapsing-remitting...
Poster-Disease-modifying Therapy
October 25, 2021
Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening Early 3 Months Post Approval Data
Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...
Poster-Disease-modifying Therapy
October 25, 2021
Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy
Background: B-cell depletion in patients with relapsing multiple sclerosis (RMS) using anti-CD20 monoclonal antibodies (mAbs) reduces...
Poster-Disease-modifying Therapy
October 25, 2021
Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study
Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World
Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....
Poster-Disease-modifying Therapy
October 25, 2021
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...